Yale Cancer Center Study Shows Rates of PSA Testing for Prostate Cancer Increased After Revised National Guidelines
In a large study led by Yale Cancer Center, more men received a prostate-specific antigen or PSA test to detect prostate cancer following revisions to the recommendation by the U.S. Preventative Services Task Force on screening.
- November 05, 2021
This month we highlight Mary Grey Maher, MD, Associate Professor of Clinical Urology. Dr. Maher talks about how the field of urology has diversified, the impact of mentors, and advice she would share with anyone pursuing a career in medicine–in her own words.
- November 03, 2021
Westerly Hospital is the first hospital in New England to use a state-of-the-art micro-ultrasound device that more precisely visualizes prostate tumors for patients undergoing prostate-specific antigen (PSA) screening and prostate biopsies. The new system allows for real-time, high-resolution imaging that guides the surgeon during the biopsy and produces images that allow the urologist to better distinguish cancerous tissue from normal tissue, which can enhance the quality of the biopsy.
- November 01, 2021Source: News12 Connecticut
Wilton police will be participating in an expanded “No-Shave November” until January by growing out their facial hair to highlight men’s health issues.No Shave November events are traditionally associated with prostate and testicular cancer. Dr. Stanton Honig, the chief of men's health at Yale Medicine, says many men's health problems can be easily solved if they're caught early, "One of the nice things about men's cancers is when they're found early, especially testicular cancer it's got a 99 percent cure rate."
- October 26, 2021Source: Urology Times
In the recent years, private equity firms have acquired many urology practices. Although this is common in other specialties, there is little known about these acquisitions in the field of urology. A recent Urology Practice study, led by Michael S. Leapman, MD, sought to investigate the trends in sudden and significant private equity acquisitions among urology practices between 2011 and 2021.
- October 05, 2021
Our first feature highlights Thomas V. Martin, MD, Associate Professor of Clinical Urology, who has been a member of Yale Urology faculty since 2013. Dr. Martin talks about his time as a Yale Urology resident and the impact it had on his career, about his role as Chair of the Clinical Operations committee, and how much the field of urology has changed in the 25 years since he was a resident–in his own words.
- September 24, 2021Source: HemeOnc Today
Nivolumab plus rucaparib demonstrated activity among men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to results of cohort A2 of the CheckMate 9KD trial presented during the virtual ESMO Congress 2021.
- September 19, 2021
Yale Cancer Center Study Finds New Drug Combination Shows Clinical Activity for Patients with Prostate Cancer
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer (mCRPC).
- September 19, 2021Source: Urology Times
Combination therapy with the PARP inhibitor rucaparib (Rubraca) and the immunotherapy nivolumab (Opdivo) demonstrated clinical activity in patients with homologous recombination deficiency–positive metastatic castration-resistant prostate cancer (mCRPC) who had no prior chemotherapy, according to findings shared during the 2021 ESMO Congress.
- September 13, 2021
My first encounter with cancer was in October 2008 when I was diagnosed with kidney cancer and needed to have my right kidney removed. A few years passed, and I thought I was done with cancer; unfortunately, I was wrong.